Novo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera

Novo Nordisk Launches Bidding War With Pfizer for Metsera Acquisition

Novo Nordisk, the Denmark-based Ozempic creator, has launched a bidding war with Pfizer Inc. to acquire New York-based Metsera Inc. Founded in 2022, Metsera is a clinical-stage biopharmaceutical firm specializing in treatments for obesity and metabolic diseases. In an Oct. 30 statement, Novo Nordisk confirmed it had submitted an unsolicited proposal to acquire Metsera. The company stated that the acquisition would complement its goals of develop…

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Metsera (NASDAQ:MTSR), Novo Nordisk (NYSE:NVO), Pfizer (NYSE:PFE)

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO). Metsera said the proposal constitutes a “Superior Company Proposal” as defined in Metsera’s existing Merger Agreement with Pfizer Inc (NYSE:PFE). In September, Pfizer agreed to acquire Metsera for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion. The acquisition brings a portfolio of diffe…

Metsera says Novo Nordisk’s $9B buyout offer “superior”; Pfizer calls bid “illusory” (NVO:NYSE)

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US rival Pfizer which called the move "reckless".

Novo Nordisk starts bidding war with Pfizer over US biotech Metsera

Novo Nordisk bid up to $8.5 billion, including $6 billion upfront and later milestone payments. Pfizer's bid was worth $7.3 billion including milestones.

Novo tries to push Pfizer aside with $9bn bid for Metsera

Novo Nordisk has launched an audacious bid to elope with weight-loss therapy developer Metsera, before it can go ahead with a marriage to Pfizer.